AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced the exercise by its underwriters of an over-allotment option to purchase 1,200,000 shares of common stock associated with its follow-on stock offering which priced on January 20, 2005. Including the over-allotment shares, the offering will total 9,200,000 shares at $22.00 per share, resulting in expected net proceeds to the company of approximately $190.5 million. Morgan Stanley & Co. Incorporated acted as the sole book running and joint lead manager for the offering. Goldman, Sachs & Co. acted as joint lead manager of the offering. Co-managers for the offering were Banc of America Securities LLC, J.P. Morgan Securities Inc., and Wachovia Capital Markets, LLC. This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A registration statement relating to these securities has been filed with and has been declared effective by the Securities and Exchange Commission. The common stock is being offered in connection with the distribution by the issuer and represents a new financing. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic disorders through the development and commercialization of innovative, cost-effective medicines. Copies of the final prospectus supplement may be obtained from the Prospectus Departments of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211), Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, phone 212-902-1171, fax 212-902-9316), Banc of America Securities LLC (9 West 57th Street, New York, NY 10019, phone 888-583-8900), J.P. Morgan Securities Inc. (1 Chase Manhattan Plaza, Floor 5B, New York, New York 10081, phone 212-552-5164) and Wachovia Capital Markets, LLC (7 St. Paul Street, Baltimore, Maryland 21202, phone 443-263-6400, fax 443-263-6894). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President of Finance and Chief Financial Officer of Amylin Pharmaceuticals, +1-858-552-2200 Web site: http://www.amylin.com/

Copyright